Furosemide 20 Milligrams
Phase 3Small molecule
Furosemide 20 Milligrams is one of 23 small molecule programs targeting Heart Failure. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Furosemide 20 Milligrams
IInstituto de Investigación Sanitaria Aragón
Phase 3
Brethine
SanofiPreclinical
Amidate
PfizerPreclinical
LCZ696
NovartisPreclinical
Zemplar
AbbViePreclinical
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Xifaxan
SSalix
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Coumadin
AAbbott
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Furosemide 20 Milligrams. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details